Semaglutide vs Tirzepatide
Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are the two most prescribed GLP-1 medications for weight loss and type 2 diabetes. The head-to-head SURMOUNT-5 trial settled the efficacy question — tirzepatide produces greater weight loss — but the choice between them involves insurance coverage, availability, tolerability, and individual response.
Tirzepatide produces more weight loss than semaglutide (20.2% vs 13.7% in head-to-head SURMOUNT-5) and is generally better tolerated. But semaglutide has something tirzepatide doesn't yet: proven cardiovascular benefit from the SELECT trial, plus an FDA-approved oral version. For pure weight loss, tirzepatide wins. For heart protection or oral dosing, semaglutide. Both are outstanding medications.
Semaglutide
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
Tirzepatide
A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.
| Category | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single) | GIP + GLP-1 dual receptor agonist |
| FDA-Approved For | Type 2 diabetes (Ozempic), weight management (Wegovy) | Type 2 diabetes (Mounjaro), weight management (Zepbound) |
| Weight Loss (Head-to-Head) | 13.7% at 72 weeks (SURMOUNT-5) | 20.2% at 72 weeks (SURMOUNT-5) |
| Cardiovascular Data | SELECT trial: 20% MACE reduction (proven) | SURPASS-CVOT (NEJM 2025): non-inferior to dulaglutide on MACE in T2D; placebo-controlled obesity outcomes trial (SURMOUNT-MMO) ongoing |
| GI Tolerability | Nausea common (~40%), especially during dose escalation | Generally better tolerated; GIP component may buffer nausea |
| Oral Option | Yes — oral semaglutide (Rybelsus 14mg, Wegovy 25mg pill) | Not yet; oral tirzepatide in development |
| Dosing | Once weekly injection (0.25–2.4mg) | Once weekly injection (2.5–15mg) |
| Compounded Availability | Narrowed — FDA's grace period for shortage-era mass compounding ended May 22, 2025; FDA says compounded versions should be used only when an approved drug can't meet a patient's medical need, and sees no lawful basis for semaglutide salt forms | Narrowed — tirzepatide is off FDA's shortage list; FDA says compounded versions should be used only when an approved drug can't meet a patient's medical need |
| Body Composition | Substantial fat loss with modest lean mass loss; similar pattern to tirzepatide (Vanderbilt, n=1,809) | Substantial fat loss with modest lean mass loss; similar pattern to semaglutide (Vanderbilt, n=1,809) |
| Long-Term Safety Data | Extensive (5+ years of post-marketing data) | Growing but less than semaglutide |
In depth
The head-to-head result
SURMOUNT-5 settled the efficacy question that the marketing wars had obscured. In a rigorous head-to-head — same trial, same population, same duration — tirzepatide produced 20.2% mean weight loss at 72 weeks versus semaglutide's 13.7%. That's a ~6.5 percentage point advantage, which is clinically meaningful (not a rounding-error edge). Tirzepatide also showed superior HbA1c reduction in diabetic populations. If the question is "which one produces more weight loss in an average patient," the answer is tirzepatide, and the evidence is now direct rather than cross-trial inferred.
Where semaglutide still wins
Semaglutide has two advantages tirzepatide currently lacks. The first is proven cardiovascular benefit. The SELECT trial (17,600+ patients with obesity but no diabetes) showed a 20% reduction in major cardiac events — heart attack, stroke, cardiovascular death — over ~3 years. That is a hard-outcomes result from a randomized trial, not a surrogate. Tirzepatide's outcomes evidence is different in kind: SURPASS-CVOT (NEJM 2025) showed non-inferiority to an active comparator (dulaglutide) in type 2 diabetes, and its placebo-controlled obesity outcomes trial (SURMOUNT-MMO) is still running. For patients with established cardiovascular disease or high CV risk where event reduction is the primary goal, semaglutide has the stronger case. The second advantage is oral availability. Semaglutide exists as Rybelsus (7mg/14mg oral tablets) and as oral Wegovy 25mg (approved January 2026 for weight management). Tirzepatide is injection-only; oral tirzepatide is in development but not approved. Patients who can't tolerate injections or need a pill have an option with semaglutide they don't with tirzepatide.
Side effects and tolerability
Both produce the GLP-1-class GI side effects (nausea, vomiting, diarrhea) — but tirzepatide is generally better tolerated despite being more effective, which is counterintuitive until you know the mechanism. The GIP receptor component of tirzepatide appears to buffer against some of the nausea that pure GLP-1 agonism causes. Nausea is the single most common reason people discontinue these medications during dose escalation, so this tolerability edge is not academic.
What about body composition
One concern that circulated heavily when these drugs became mainstream was muscle loss — that a lot of the "weight lost" might be lean mass, leaving patients with worse body composition. A large Vanderbilt study (1,809 patients, JAMA Network Open 2026) clarified this: both drugs produce substantial fat reduction with modest lean mass loss and improved muscle-to-fat ratio, comparable to bariatric surgery patterns. Males preserved lean mass better than females. The meaningful finding is that body composition outcomes between semaglutide and tirzepatide are similar — not a major differentiator in either direction.
Bottom line
For pure weight loss magnitude: tirzepatide. For proven cardiovascular benefit in obesity: semaglutide. For oral dosing: semaglutide. For GI tolerability: tirzepatide edges. For access: often whichever your insurance covers. Both are genuinely excellent medications with strong long-term safety data (semaglutide has more post-marketing surveillance because it's been out longer). This is not good-vs-bad; this is good-vs-better in a category where even "good" is transformative.
These peptides are often used together. See our stack profiles for combination details.